TY - JOUR
T1 - Common Pathways in Depression and Obesity
T2 - The Role of Gut Microbiome and Diets
AU - Inta, Dragos
AU - Wölnerhanssen, Bettina K.
AU - Meyer-Gerspach, Anne Christin
AU - Lang, Elisabeth
AU - Schweinfurth, Nina
AU - Mallien, Anne S.
AU - Vasilescu, Andrei Nicolae
AU - Schmidt, André
AU - Rea, Kieran
AU - Westendorf, Astrid M.
AU - Tremblay, Marie Ève
AU - Sartorius, Alexander
AU - Gass, Peter
AU - Cryan, John F.
AU - Borgwardt, Stefan
AU - Lang, Undine E.
N1 - Publisher Copyright:
© 2020, Springer Nature Switzerland AG.
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Purpose of Review: This paper aims to review data regarding two determinants of comorbidity between depression and obesity, i.e., the role of disturbed gut microbiome in their genesis and of diets in their treatment. Recent Findings: Obesity and major depressive disorders (MDD) are highly comorbid, the “metabolic” (obese) subtype of MDD affects about one third of all individuals with MDD. There is an urgent need for better therapies strategies, which may include specific dietary measures. A diet low in carbohydrates (low-carb), effective in obesity, may be beneficial also in MDD. However, the underlying mechanisms have not yet been elucidated. Recent data suggest a key role of gut microbiota, neuroplasticity, and neuroinflammation in obesity and MDD. We will focus on the brain-derived neurotrophic factor (BDNF), and microglial fractalkine, a main modulator of neuroinflammation. Summary: BDNF and fractalkine may be involved in “metabolic” depression. Future studies may uncover specific pathophysiological pathways in affected patients towards more efficient causal therapies.
AB - Purpose of Review: This paper aims to review data regarding two determinants of comorbidity between depression and obesity, i.e., the role of disturbed gut microbiome in their genesis and of diets in their treatment. Recent Findings: Obesity and major depressive disorders (MDD) are highly comorbid, the “metabolic” (obese) subtype of MDD affects about one third of all individuals with MDD. There is an urgent need for better therapies strategies, which may include specific dietary measures. A diet low in carbohydrates (low-carb), effective in obesity, may be beneficial also in MDD. However, the underlying mechanisms have not yet been elucidated. Recent data suggest a key role of gut microbiota, neuroplasticity, and neuroinflammation in obesity and MDD. We will focus on the brain-derived neurotrophic factor (BDNF), and microglial fractalkine, a main modulator of neuroinflammation. Summary: BDNF and fractalkine may be involved in “metabolic” depression. Future studies may uncover specific pathophysiological pathways in affected patients towards more efficient causal therapies.
UR - http://www.scopus.com/inward/record.url?scp=85090083347&partnerID=8YFLogxK
U2 - 10.1007/s40473-020-00199-1
DO - 10.1007/s40473-020-00199-1
M3 - Scientific review articles
AN - SCOPUS:85090083347
SN - 2196-2979
VL - 7
SP - 15
EP - 21
JO - Current Behavioral Neuroscience Reports
JF - Current Behavioral Neuroscience Reports
IS - 1
ER -
